NO962943L - Peptider og fremgangsmåte mot psoriasis - Google Patents

Peptider og fremgangsmåte mot psoriasis

Info

Publication number
NO962943L
NO962943L NO962943A NO962943A NO962943L NO 962943 L NO962943 L NO 962943L NO 962943 A NO962943 A NO 962943A NO 962943 A NO962943 A NO 962943A NO 962943 L NO962943 L NO 962943L
Authority
NO
Norway
Prior art keywords
psoriasis
present
cell
peptide
fragment
Prior art date
Application number
NO962943A
Other languages
English (en)
Other versions
NO962943D0 (no
Inventor
Jennie C C Chang
Steven W Brostoff
Dennis J Carlo
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of NO962943D0 publication Critical patent/NO962943D0/no
Publication of NO962943L publication Critical patent/NO962943L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)

Abstract

Foreliggende oppfinnelse vedrører fremgangsmåter for forebyggelse eller reduksjon i styrke av psoriasis. I en utførelsesform involverer fremgangs- måten administrering av et peptid med hovedsakelig sekvensen til et ikke-kon- servert område av en T-cellereseptor tilstede på overflaten av psoriasis- formidlende T-celler eller et fragment derav, til et individ, hvori peptidet eller fragmentet har evnen til å forår- sake en virkning på immunsystemet i form av T-celleregulering. Særlig har T-cellereseptoren V(33, V(53,l eller | V(317. Dessuten omfatter fremgangsmåten ! genterapi. Foreliggende oppfinnelse ', vedrører også fremgangsmåter for i diagnostisering av psoriasis ved hjelp av bestemmelse av tilstedeværelse av psoriasisassosierte T-cellereseptorer.
NO962943A 1994-01-14 1996-07-12 Peptider og fremgangsmåte mot psoriasis NO962943L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/182,967 US6413516B1 (en) 1989-03-21 1994-01-14 Peptides and methods against psoriasis
PCT/US1995/000658 WO1995019375A1 (en) 1994-01-14 1995-01-13 Peptides and methods against psoriasis

Publications (2)

Publication Number Publication Date
NO962943D0 NO962943D0 (no) 1996-07-12
NO962943L true NO962943L (no) 1996-09-13

Family

ID=22670842

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962943A NO962943L (no) 1994-01-14 1996-07-12 Peptider og fremgangsmåte mot psoriasis

Country Status (14)

Country Link
US (1) US6413516B1 (no)
EP (1) EP0738281B1 (no)
JP (2) JPH09508112A (no)
CN (1) CN1138865A (no)
AT (1) ATE227738T1 (no)
BR (1) BR9506511A (no)
CA (1) CA2179280A1 (no)
DE (1) DE69528817T2 (no)
ES (1) ES2184791T3 (no)
FI (1) FI962836A7 (no)
MX (1) MX9602473A (no)
NO (1) NO962943L (no)
NZ (1) NZ279987A (no)
WO (1) WO1995019375A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
JP2009266963A (ja) * 2008-04-23 2009-11-12 Sumitomo Electric Ind Ltd 窒化物系発光素子、及び半導体発光素子を製造する方法
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
TW202227495A (zh) * 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
EP4277645A1 (en) 2021-12-16 2023-11-22 Ramakrishna Reddy Isanaka A stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and prevention of psoriasis
CN116466095B (zh) * 2023-06-15 2023-09-01 朗肽生物制药股份有限公司 一种多肽及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570027B1 (en) * 1984-03-01 1999-12-29 The Board Of Trustees Of The Leland Stanford Junior University T cell receptor-specific for antigen polypeptides and related polynucleotides
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
IL95125A (en) * 1989-07-19 1995-07-31 Vandenbark Arthur Allen T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
WO1993006135A1 (en) 1991-09-23 1993-04-01 Genentech, Inc. Diagnosing and treating autoimmune disorders
CA2126686A1 (en) * 1991-12-24 1993-07-08 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Also Published As

Publication number Publication date
AU697910B2 (en) 1998-10-22
US6413516B1 (en) 2002-07-02
EP0738281A1 (en) 1996-10-23
EP0738281B1 (en) 2002-11-13
CN1138865A (zh) 1996-12-25
AU1728295A (en) 1995-08-01
MX9602473A (es) 1997-05-31
DE69528817D1 (de) 2002-12-19
ES2184791T3 (es) 2003-04-16
FI962836L (fi) 1996-07-12
NO962943D0 (no) 1996-07-12
DE69528817T2 (de) 2003-09-11
JPH09508112A (ja) 1997-08-19
CA2179280A1 (en) 1995-07-20
BR9506511A (pt) 1997-09-09
FI962836A0 (fi) 1996-07-12
JP2001288108A (ja) 2001-10-16
FI962836A7 (fi) 1996-07-12
WO1995019375A1 (en) 1995-07-20
NZ279987A (en) 1999-09-29
ATE227738T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
Lobb et al. Immunoglobulin light chain classes in a teleost fish.
Maggi The mammalian tachykinin receptors
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
EP0815125A4 (en) gC1q RECEPTOR, BINDING HIV-1 gp120 REGION, RELATED PEPTIDES AND ANTIBODIES
DE69738432D1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
AU1986588A (en) Growth hormone receptor
DE59101889D1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
CA2296737A1 (en) Ligand for herpes simplex virus entry mediator and methods of use
NO962943L (no) Peptider og fremgangsmåte mot psoriasis
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
ATE282634T1 (de) Chaperonin 10
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
NO963366L (no) Peptider og fremgangsmåte for behandling av diabetes
AU3384495A (en) Or-1 on orphan receptor belonging to the nuclear receptor family
MY127669A (en) Polypeptide hormone phosphatonin
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
NO20006456L (no) En mutant human hepatitt B viral stamme og anvendelser derav
WO1996023070A3 (en) HUMAN RETINOID X RECEPTOR - GAMMA (hRXR-GAMMA)
Czarnocka et al. Further Evidence that Thyroid Peroxidase and the “Microsomal Antigen” are the Same Entity
KR930019827A (ko) 신규 폴리펩티드 및 이를 암호하는 dna
Ferrand et al. B. Czarnocka, J. Ruf, C. Alquier*, ME Toubert, C. Dutoit
NZ334649A (en) Iron regulated promoter derived from an aerobactin gene promoter
NO996210L (no) Peptider og forbindelser som bindes til IL-5-reseptorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application